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The aberrant activation of ErbB family
receptor tyrosine kinases (RTKs), includ-
ing the EGF receptor, ErbB2 (also called
HER2/neu), ErbB3, and ErbB4, has
been implicated in tumor growth and pro-
gression. One mechanism by which
these receptors may be activated in
tumor cells is through overexpression,
which can either promote constitutive
receptor dimerization or overwhelm neg-
ative regulatory mechanisms that keep
receptor activity in check. EGF receptor
and ErbB2 are overexpressed in a vari-
ety of solid tumors, and overexpression
often correlates with reduced time to
relapse and poor prognosis. These
observations point to ErbB receptors as
therapeutic targets, and the clinical suc-
cess and administrative approval of the
ErbB2-directed Herceptin for breast can-
cer patients whose tumors overexpress
this receptor provide proof of this princi-
ple (Shawver et al., 2002).
Certainly ErbB receptor overexpres-
sion can lead to ligand-independent acti-
vation, constitutive signaling, and the
promotion of tumor growth and progres-
sion. However, while receptor overex-
pression is a readily recognizable clinical
marker for aggressive tumors, mechanis-
tically overexpression may underrepre-
sent the role of ErbB receptors in tumor
growth.The autocrine production of ErbB
binding epidermal growth factor (EGF)-
like ligands by tumor cells or the tumor-
induced production of ligands by sur-
rounding stromal cells has also been
implicated in ErbB-mediated tumor
growth. Moreover, progress in the field in
recent years has uncovered a plethora of
mechanisms leading to ErbB receptor
activation by heterologous cell surface
proteins. This point is highlighted by the
findings of Liu et al. (2002) in this issue of
Cancer Cell, which suggest that the
overexpression of the urokinase plas-
minogen activator receptor (uPAR) can
mediate the activation of normal levels of
EGF receptor.
Urokinase plasminogen activator
(uPA), an extracellular serine protease,
functions in conjunction with its GPI-
linked cell surface receptor uPAR in the
creation of the active plasmin protease.
Several decades of study have pointed
to a causal role for the plasminogen acti-
vation system in tumor cell invasion and
metastasis, and uPA and uPAR overex-
pression in many tumor types predicts a
poor patient prognosis (Andreasen et al.,
1997). Interestingly, at least some of the
activities ascribed to the plasminogen
activation system appear to be indepen-
dent of protease function. uPAR is capa-
ble of mediating the activation of intracel-
lular signaling cascades such as the
Erk1/2 MAP kinases despite its lack of
an intracellular domain. The interaction
of uPAR with integrins accounts for its
signaling activity and suggests a role for
this receptor in the coordination of cellu-
lar adhesion, migration, and growth
(Ossowski and Aguirre-Ghiso, 2000;
Preissner et al., 2000).
Liu et al. report that the EGF receptor
plays a central role in mediating cellular
growth signals initiated by uPAR and inte-
grins.When overexpressed in a head and
neck carcinoma cell line that expresses
modest levels of EGF receptor, uPAR
associated with and activated the α5β1
integrin complex. Plating these cells on
fibronectin (FN) promoted the recruit-
ment of the EGF receptor to integrins,
stimulated the tyrosine phosphorylation
of the EGF receptor, and enhanced Erk
activity (Figure 1). FN-stimulated EGF
receptor activity appeared to be indepen-
dent of RTK overexpression or the ex-
pression or release of EGF-like growth
factors, and was only dependent on the
overexpression of uPAR and the function-
al integrity of the uPA/uPAR/FN/integrin
complex. Inhibitor studies suggested that
EGF receptor activity was responsible for
FN-stimulated Erk activation and for
tumor cell growth in a chick chorioallanto-
ic membrane (CAM) assay. One implica-
tion of their results is that uPAR overex-
pression could facilitate both tumor
growth and invasion through its multi-
functional nature.
EGF receptor activation by heterologous mechanisms
A myriad of growth factor-dependent and -independent mechanisms for activating the EGF receptor and the related ErbB
receptors underscore the importance of receptor inhibitors in the treatment of some solid tumors.
Figure 1. Heterologous ligand-dependent
and -independent EGF receptor activation
mechanisms
Stimulation of some GPCRs has been
demonstrated to induce the release of
membrane bound EGF-like growth factor
(GF) ligands, which are then free to activate
the EGF receptor in an autocrine manner.
Overexpression of uPAR primes α5β1 integrins
to activate EGF receptor upon fibronectin
(FN) binding, possibly through a FAK-depen-
dent mechanism. Receptor activation leads
to the activation of downstream kinases
such as Erk1, Erk2, Erk5, and Akt, and the
accompanying regulation of gene expres-
sion patterns that can lead to the growth
and invasive properties of tumor cells. Genes
encoding EGF-like growth factors are often
targets receptor activation, leading to a
positive feedback or amplification loop.
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These results are consistent with
numerous reports indicating that ErbB
receptors are capable of mediating sig-
naling from a variety of heterologous
stimuli (Carpenter, 1999). Heterologous
ErbB receptor activation can involve
either growth factor ligand-dependent or
-independent mechanisms, but result in
MAP kinase activation via processes
that are most often dependent on recep-
tor tyrosine kinase activity. For example,
transactivation of EGF receptors by 
G protein-coupled receptors (GPCRs)
such as the lysophosphatidic acid (LPA)
receptor has been demonstrated to
induce the shedding of membrane-teth-
ered EGF-like ligand precursors by met-
alloproteases (Gschwind et al., 2001).
Cytokine receptors such as those for
growth hormone and IL6 can interact
with the EGF receptor and ErbB2,
respectively, to mediate MAPK activation
in response to their ligands. Finally,
membrane depolarization and cellular
stresses such as exposure to UV irradia-
tion or oxidants can also lead to MAP
kinase activation through the EGF recep-
tor (Weiss et al., 1997).
The observations of Liu et al. are
also consistent with the emerging theme
that overexpression of some cell surface
proteins could unmask or augment their
ErbB activation activities. For example,
the mucins MUC1 and MUC4 play roles
in the normal protection and lubrication
of epithelial surfaces, but are commonly
found overexpressed in a variety of
malignant tumors. Because their size
and highly negative charge disrupt cell-
cell and even cell-protein interactions,
mucins are thought to contribute to tumor
cell evasion of immune surveillance.
However, both MUC1 and MUC4 have
been shown to interact with ErbB recep-
tor family members and to potentiate sig-
naling (Schroeder et al., 2001) and cellu-
lar growth properties (Komatsu et al.,
2001). While the physiological signifi-
cance of this functional duality in normal
tissue development or maintenance
remains to be determined, aberrant ErbB
activation by overexpressed mucins
could actively contribute to the growth or
progression of tumor cells (Carraway et
al., 2001). Like uPAR, the mucins appear
to exert their effects on ErbB receptors in
the absence of RTK overexpression.
The results described above encom-
pass dozens of individual reports and
emphasize that there is remarkable
plasticity in the activation of the ErbB
RTKs. ErbB activation mechanisms
appear to be more prevalent in tumor
cells that overexpress some heterolo-
gous cell surface proteins, but ErbB
receptor overexpression is not neces-
sary. Hence, it is quite likely that aber-
rant ErbB receptor activation plays a
more far-reaching role in tumor growth
and progression than is represented by
overexpression. Moreover, most of the
described mechanisms involve the acti-
vation of receptor tyrosine kinase activity
itself, as opposed to crossphosphoryla-
tion of receptors by other kinases to
serve as a scaffold for the initiation of
signaling events. These observations
suggest that ErbB-directed tyrosine
kinase inhibitors such as the small mole-
cule EGF receptor inhibitor Iressa, which
in preclinical studies exhibits some
growth inhibitory effects toward EGF
receptor-overexpressing non-small cell
lung cancers (Raben et al., 2002), could
possibly impact a wider subset of tumors
than those that overexpress receptors.
For the future it will be important to deter-
mine the extent to which ErbB receptors
are aberrantly activated in tumors where
overexpression is not observed. The
development of highly sensitive phos-
pho-specific antibodies directed toward
active receptors could help alleviate
some of the technical barriers in this
regard.
Kermit L. Carraway III1
and Colleen Sweeney
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Myc—Is this the oncogene from Hell?
A new paper implicates the Myc oncoprotein in the direct induction of DNA damage and consequent genome instability in
cultured cells. However, it is less clear whether Myc induces the same genetic pandemonium in vivo.
The corrupted genomes of most human
epithelial cancers are, like the Yucatan
crater formed by the meteor that wiped
out the dinosaurs, unambiguous relics of
some catastrophic calamity within the
tumor cell, a salient reminder of the
genomic abyss that opens when the
mechanisms that maintain chromosomal
integrity fail or are overridden. Indeed, so
